Stay updated on Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The web page has updated its date-related content, adding several new dates for events in 2025 while removing some previous dates.
    Difference
    0.6%
    Check dated 2025-05-02T22:08:05.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-25T17:54:42.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of new drug names and identifiers related to renal cell carcinoma treatments, while substantial content regarding the study's details and inclusion/exclusion criteria has been removed.
    Difference
    22%
    Check dated 2025-04-18T14:23:18.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The date has been updated from March 25, 2025, to February 26, 2025.
    Difference
    0.2%
    Check dated 2025-04-11T10:33:57.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-03T21:47:12.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of February 26, 2025, and version 2.14.2.
    Difference
    0.2%
    Check dated 2025-03-27T14:46:06.000Z thumbnail image

Stay in the know with updates to Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.